Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

126
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
126
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

226
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
226
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

453
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
453
Drug Therapy01:28

Drug Therapy

42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
42
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

467
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the relationship of exposure to adverse childhood experiences and pain in healthy subjects.

Fortschritte der Neurologie-Psychiatrie·2026
Same author

Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional Study.

Community mental health journal·2026
Same author

Real-World Effectiveness of the Peer-Led Honest, Open, Proud Programme for Self-Stigma Among Adults With Mental Illness: A Pragmatic, Multicentre, Randomised Controlled Trial.

The Lancet regional health. Europe·2026
Same author

Cognitive effects of transcranial random noise stimulation in schizophrenia: A triple-blind randomized placebo-controlled pilot study.

Journal of psychiatric research·2026
Same author

Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial.

Communications medicine·2026
Same author

Evaluation of a transdiagnostic mental health intervention in German primary care: a parallel-group, two-arm, cluster randomised controlled pilot study.

BMC primary care·2026

Related Experiment Video

Updated: Jun 26, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

666

[Deprescribing in DGPPN S3 guidelines-a systematic analysis].

Selina Seitz1, Alkomiet Hasan2,3, Wolfgang Strube2

  • 1Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Medizinische Fakultät, Universität Augsburg, Augsburg, Deutschland. selina.seitz@med.uni-augsburg.de.

Der Nervenarzt
|May 17, 2024
PubMed
Summary

Deprescribing medication and psychotherapy are critical treatment phases. Current German guidelines lack sufficient evidence-based recommendations, indicating a need for improved deprescribing guidance for patients and clinicians.

Keywords:
DiscontinuationDosis reductionGuidelinesPsychotherapyPsychotropic medication

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

504
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Related Experiment Videos

Last Updated: Jun 26, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

666
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

504
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Area of Science:

  • Psychiatry
  • Psychotherapy
  • Pharmacology

Background:

  • Deprescribing medication and discontinuing psychotherapy are crucial treatment steps.
  • Systematic analysis of guidelines is needed to identify research gaps in deprescribing.

Purpose of the Study:

  • To systematically analyze recommendations for deprescribing medication and psychotherapy in German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) S3 guidelines.
  • To identify potential research gaps in current deprescribing guidelines.

Main Methods:

  • Systematic analysis of DGPPN S3 guidelines.
  • Investigating and comparing information and recommendations on deprescribing medication and psychotherapy.

Main Results:

  • Eight of 20 S3 guidelines included information on medication deprescribing.
  • Only two guidelines provided information on psychotherapy deprescribing.

Conclusions:

  • Guidelines need expansion to include evidence-based recommendations for medication deprescribing and psychotherapy discontinuation.
  • Future research should focus on developing specific, generic, evidence-based guidelines for deprescribing.